Hola,
Are you new here?

SOPHIA

financed

Stratification of Obesity Phenotypes to Optimize Future Therapy

SOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of self-control, rather than a disease. We will change this perspective by defining subpopulatio... see more

31/05/2025

NUID UCD

17M€

Project Budget: 17M€

Project leader

UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 37 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2025-05-31

IMI2-2019-17-01: Optimising future obesity treatment Specific Challenge:The prevalence of obesity is increasing and affects more than 650 million people...

I+D

Cerrada does 6 years

0% 49% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

37 Participantes

NUID UCD

1.59M€ | Leader

Eli Lilly

750.00K€ | participant

METABOLON GMBH

464.13K€ | participant

UCC

20.00K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 60 months Date Start: 2020-05-26
End date: 2025-05-31

Project leader

UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 17M€

participation deadline Sin fecha límite de participación.

Project description SOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of self-control, rather than a disease. We will change this perspective by defining subpopulations in terms of (a) the risks of complications linked to obesity, (b) response to various obesity treatments. The subpopulations will be characterised in terms of operational variables (phenotypic, genetic, behavioural, environmental, and omics). These predictive variables will facilitate diagnosis and underpin personalised and protocolised obesity care. Patient priorities regarding risk and response will influence all aspects of our work. SOPHIA will create a federated database of premier EU cohorts to identify operational variables that are predictive of risk and treatment response in people with and without diabetes. We will validate the predictive value of these variables before creating clinically-useful algorithms to decide when-to-treat and how-to-treat. Biomarker variables will feed into innovative assays, tests and research targets. We will interpret and analyse our results, to identify shared value across all stakeholders (patients, clinicians, industry, payers). SOPHIA will change attitudes and experience of obesity by (1) demonstrating the heterogeneity of the disease, (2) identifying people at risk of complications, (3) identifying the best treatment for each individual, (4) delivering a common vocabulary and shared understanding of obesity, (5) demonstrating shared value, which combines commercial opportunity with societal benefit. Our ambition will only be realised if (a) payers agree to fund treatment, (b) industry generate effective treatments, (c) clinicians are prepared to prescribe treatments, and (d) patients are prepared to take treatments. The evidence base does not currently exist. SOPHIA will deliver this evidence and the shared value analysis to drive this revolution in obesity care.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers